99TiP A randomized phase II study of lazertinib alone versus lazertinib plus bevacizumab for advanced non-small cell lung cancer with epidermal growth factor receptor activating mutations and smoking history
ESMO Open（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined